Update shared on 03 Dec 2025
Analysts have modestly raised their price target on Xvivo Perfusion to SEK 225 from SEK 319.6, reflecting increased confidence in the company’s long term growth potential following recent research upgrades.
Analyst Commentary
Bullish analysts view the recent upgrade and revised target as a signal that Xvivo Perfusion is entering a more robust execution phase, with clearer line of sight to its long term growth ambitions.
Bullish Takeaways
- Bullish analysts see the SEK 225 target as justified by stronger confidence in Xvivo Perfusion’s ability to convert its technology pipeline into recurring, high margin revenue streams.
- They point to improving visibility on procedure volumes and adoption rates as supporting a higher growth trajectory. In their view, this underpins multiple expansion from current valuation levels.
- Execution on commercialization and market penetration is viewed as de risked compared with prior expectations. This is seen as narrowing the gap between the company’s strategic potential and its current share price.
- Analysts highlight that the balance of risk and reward has tilted more favorably, with near term catalysts in clinical and regulatory milestones seen as potential drivers for further upside.
Bearish Takeaways
- Bearish analysts caution that even after the upgrade, the implied valuation leaves limited room for error if growth in transplant related procedures slows or adoption timelines extend.
- They remain wary of execution risks around scaling manufacturing and securing consistent hospital level reimbursement, which could pressure margins and delay earnings leverage.
- Concerns persist that competitive technologies or shifting clinical guidelines could cap long term market share, challenging the assumptions embedded in the higher price target.
- Some analysts note that macroeconomic uncertainty and healthcare budget constraints may weigh on capital spending, potentially tempering the pace at which new centers adopt the company’s solutions.
Valuation Changes
- Fair Value Estimate unchanged at SEK 319.6, indicating no revision to the intrinsic value assessment despite the recent rating upgrade.
- Discount Rate risen slightly from 5.77 percent to 5.79 percent, reflecting a marginally higher assumed risk profile in the valuation model.
- Revenue Growth effectively unchanged at around 23.0 percent, signaling stable expectations for the company’s top line expansion.
- Net Profit Margin essentially flat at approximately 21.7 percent, suggesting no material shift in long term profitability assumptions.
- Future P/E edged up slightly from 35.74 times to 35.76 times, implying a modestly higher multiple applied to forward earnings.
Have other thoughts on Xvivo Perfusion?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.